The Journal of Clinical Psychiatry January-December 1992: Vol 53 Index

13 Pages·5.2 MB·English

Journal of Clinical Psychiatry
Subject Index to Volume 53: January 1992 Through December 1992
ACADEMIC Hicuucrts Dec 450-451 19-22
New directions in antidepressant therapy: a re- Anorexia Nervosa see also Bulimia; Eating Closing remarks. Use of benzodiazepine hypnot-
view of sertraline, a unique serotonin reup- Disorders ics: a scientific examination of a clinical con-
take inhibitor. Sept 333-340 Preliminary investigation of the lifetime preva- troversy. Gelenberg, Dec suppl 87
Novel selective serotonin reuptake inhibitors, lence of anorexia and bulimia nervosa in pa- Closing remarks. Use of benzodiazepine hypnot-
part I. Mar 107-112 tients with obsessive compulsive disorder. ics: a scientific examination of a clinical con-
Novel selective serotonin reuptake inhibitors, Rubenstein, Sept 309-314 troversy. Kupfer, Dec suppl 84-85
part II. June 216-221 Anticholinergic Agents Closing remarks. Use of benzodiazepine hypnot-
Acquired Immunedeficiency Syndrome “Gedankenlautwerden” and datura intoxication ics: a scientific examination of a clinical con-
AIDS-related psychosis with catatonia {letter]. Goates, Apr 137 troversy. Wincor, Dec suppl 85-87
responding to low-dose lorazepam [letter]. Antidepressants see also specific drugs Comparative clinical profiles of triazolam versus
Scamvougeras, Nov 414-415 Acute tryptophan depletion: a method of study- other shorter-acting hypnotics. Jonas, Dec
Catatonia in a patient with AIDS-related de- ing antidepressant action. Miller, Oct suppl suppl 19-31
mentia [letter]. Snyder, Nov 414 28-35 Introduction. Use of benzodiazepine hypnotics:
Methylphenidate as a treatment for depression Imperfect drugs in an imperfect world [edito- a scientific examination of a clinical contro-
in acquired immunodeficiency syndrome: an rial]. Gelenberg, Feb 39-40 versy. Gelenberg, Dec suppl 3
n-of-1 trial. White, May 153-156 Introduction. Issues in the treatment of major Issues in the use of benzodiazepine therapy.
Adolescents depression: selection, efficacy, and safety. Roth, June suppl 14-18
Childhood obsessive compulsive disorder. Blazer, Sept suppl 3-4 Pharmacology of benzodiazepine hypnotics.
Rapoport, Apr supp! 11-16 Medical consequences of the selection of an an- Greenblatt, June suppl 7-13
Misdiagnosed bipolar disorder in adolescents in tidepressant. Nierenberg, Sept suppl 19-24 Bipolar Disorder
a special educational school and treatment Nifedipine and nonresponse to antidepressants Bipolar disorder and Crohn’s disease [letter].
program. Isaac, Apr 133-136 [letter]. Fadden; Nierenberg reply, Nov 416— Dommisse, Jan 29
Affective Disorders see also Bipolar Disor- 417 Bupropion in the treatment of bipolar disorders:
der; Depression; Mania; Seasonal Affec- Somatic therapy for major depressive disorder: the same old story? Fogelson, Dec 443-46
tive Disorder selection of an antidepressant. Preskorn, Sept Fluoxetine and bupropion treatment of bipolar
Introduction and overview to clinical appli- suppl 5-18 disorder, type II, associated with GAD [let-
cations of neuroSPECT in psychiatry. T3 augmentation of antidepressant treatment in ter]. Novac, Feb 67
Schuckit, Nov suppl 3-6 T4-replaced thyroid patients. Cooke, Jan 16— Misdiagnosed bipolar disorder in adolescents in
Agitation 18 a special educational school and treatment
New possible indications of pimozide [letter]. Treating the depressed patient with cardiovascu- program. Isaac, Apr 133-136
Iruela; Opler reply, May 172-173 lar problems. Roose, Sept suppl 25-31 Blood Levels
Agranulocytosis Tricyclic antidepressant-induced seizures and Do monoamine oxidase inhibitors alter carba-
Clozapine-induced agranulocytosis in a native plasma drug concentration. Preskorn, May mazepine blood levels [letter]? Jefferson, July
American: HLA typing and further support 160-162 258
for an immune-mediated mechanism. Pfister, Tricyclic antidepressant triggers mania in pa- Ratio of plasma fluoxetine to norfluoxetine con-
July 242-244 tient with organic affective disorder [letter]. centrations and associated sedation. Keck Jr,
Granulocyte-macrophage colony-stimuiating Santos, Oct 377-378 Apr 127-129
factor (GM-CSF) treatment of clozapine-in- Anxiety Tricyclic antidepressant-induced seizures and
duced agranulocytosis: a case report. Barnas, Fluoxetine and bupropion treatment of bipolar plasma drug concentration. Preskorn, May
July 245-247 disorder, type II, associated with GAD [let- 160-162
Akathisia ter]. Novac, Feb 67 Books Reviewed
Akathisia, suicidality, and fluoxetine. Hamilton, Regional cerebral blood flow imaging with Addonizio G, Susman VL: Neuroleptic Malig-
Nov 401-406 SPECT in psychiatric disease: focus on nant Syndrome: A Clinical Approach. Gold
Should chronic treatment-refractory akathisia schizophrenia, anxiety disorders, and sub- Jr, Jan 31
be an indication for the use of clozapine in stance abuse. Woods, Nov suppl 20-25 Amchin J: Psychiatric Diagnosis: A Biopsych-
schizophrenic patients? Levin, July 248-251 Autism osocial Approach. Djenderedjian and Ritchie,
Allergic Reaction Double-blind, placebo-controlled study of the July 259-260
Injection site reactions [letter]. Hay, July 256 efficacy of transdermal clonidine in autism. Arndt AB Jr: Gender Disorders and the
Alpidem Fankhauser, Mar 77-82 Paraphilias. Segraves, June 215
Clarification of alpidem as an antidepressant Baclofen : Becker J, Kleinman A (eds): Psychosocial As-
[letter]. George; Tollefson reply, Feb 68-69 Case of baclofen-induced psychotic depression pects of Depression. Keitner, Feb 71
Alzheimer’s Disease see also Dementia [letter]. Sommer, June 211-212 Becker RE, Giacobini E (eds): Alzheimer’s Dis-
Nonsedating treatments for Alzheimer’s pa- Behavioral Disorders ease: Current Research in Early Diagnosis.
tients with behavioral problems [letter]. Nonsedating treatments for Alzheimer’s patients Cummings, Mar 105
Hawkins; Goad reply, Mar 101-102 with behavioral problems [letter]. Hawkins; Butcher JN, Graham JR, Williams CL, Ben-
Amantadine Goad reply, Mar 101-102 Porath YS: Development and Use of the
Treatment of fluoxetine-induced anorgasmia Benzodiazepines MMPI-2 Content Scales. Kores, Mar 105-
with amantadine [letter]. Balogh, June 212- Clinical distinctions between long-acting and 106
213 short-acting benzodiazepines. Mendelson, Committee on Psychiatry and Law of the Group
Amphetamine Dec suppl 4-7 for the Advancement of Psychiatry: The Men-
Is tranylcypromine really metabolized to am- Clinical uses and advantages of low doses of tal Health Professional and the Legal System.
phetamine [letter]? Jefferson; Zajecka reply, benzodiazepine hypnotics. Vogel, June suppl Tanay, Feb 70
J Clin Psychiatry 53:12, December 1992
Subject Index: Volume 53
Cutting J: The Right Cerebral Hemisphere and Practice in the Juvenile Court. Bernet, Sept mazepine blood levels [letter]? Jefferson, July
Psychiatric Disorders. Nasrallah, Apr 140 331 258
Dulcan MK, Popper CW: Concise Guide to Trad PV: Interventions With Infants and Par- Cardiovascular Diseases
Child and Adolescent Psychiatry. Hill, Feb ents: The Theory and Practice of Previewing. Treating the depressed patient with cardiovascu-
70-71 Soltys, Nov 418-419 lar problems. Roose, Sept suppl 25-31
Esman AH: Adolescence and Culture. King, Turner SM, Calhoun KS, Adams HE (eds): Catatonia
Aug 298 Handbook of Clinical Behavior Therapy. AIDS-related psychosis with catatonia
Evangelista A: Dictionary of Hypnotism. Battle, Mavissakalian, Nov 419 responding to low-dose lorazepam [letter].
Mar 106 Volkow ND, Wolf AP (eds): Positron Emission Scamvougeras, Nov 414-415
Exner JE Jr: The Rorschach: A Comprehensive Tomography in Schizophrenia Research. Catatonia associated with bupropion treatment
System, Vol. 2: Interpretation, 2nd Ed. Battle, Goid Jr, Apr 140 [letter]. Jackson, June 210
Sept 331-332 Weeks GR (ed): Promoting Change Through Catatonia in a patient with AIDS-related demen-
Falco KL: Psychotherapy With Lesbian Clients: Paradoxical Therapy, rev. ed. Rodgers, July tia [letter]. Snyder, Nov 414
Theory Into Practice. Surawicz, Sept 332 260 NMS and lethal catatonia [letter]. Weller:
Feinstein SC (ed): Adolescent Psychiatry, Vol- Weiner MF (ed): The Dementias: Diagnosis and DasGupta reply, Aug 294-295
ume 17. Pomeroy, Feb 71 Management. Stoudemire, July 260 Cerebral Blood Flow
Greenspan SL, Greenspan NT: The Clinical In- Winokur G: Mania and Depression: A Classifi- Regional cerebral blood flow imaging with
terview of the Child. Utley, June 214-215 cation of Syndrome and Disease. Amado, SPECT in psychiatric disease: focus on
Harper-Giuffre H, MacKenzie KR (eds): Group Dec 452 schizophrenia, anxiety disorders, and sub-
Psychotherapy for Eating Disorders. Yates A: Compulsive Exercise and the Eating stance abuse. Woods, Nov suppl 20-25
Larocca, Nov 418 Disorders: Toward an Integrated Theory of Cerebral Stroke
Hendren RL, Berlin IN (eds): Psychiatric Inpa- Activity. Casper, Apr 141 Depression and cerebrai stroke. Catapano, 1990
tient Care of Children and Adolescents: A Brain Disorders Sept suppl 9-12; Notice to the readers, Aug
Multi-Cultural Approach. Soltys, Apr 140- Fluvoxamine-induced frontal lobe syndrome in a 293
141 patient with comorbid Gilles de la Tourette’s Efficacy and side effects of methylphenidate for
Horowitz MJ (ed): Person Schemas and Mal- syndrome and obsessive compulsive disorder poststroke depression. Lazarus, Dec 447-449
adaptive Interpersonal Patterns. St. John, [letter]. George; Hoehn-Saric reply, Oct 379- Cerebrovascular Disorders
Sept 331 380 Comparison of SPECT applications in neurol-
Howells JG (ed): The Concept of Schizophrenia: Brain Injuries ogy and psychiatry. Devous, Nov suppl 13-
Historical Perspectives. Gold Jr, May 175-— Head injury and mood disturbance [letter]. 19
176 Miller, May 171-172 Children
Koulack D: To Catch a Dream. Mendelson, Methylphenidate and seizure frequency in brain Childhood obsessive compulsive disorder.
Aug 297 injured patients with seizure disorders. Rapoport, Apr supp! 11-16
Levine SB: Sex Is Not Simple. Surawicz, Jan 32 Wroblewski, Mar 86-89 Chronic Fatigue Syndrome
Lewis JM: Swimming Upstream: Teaching and Bulimia see also Anorexia Nervosa; Eating Pathogenesis of chronic fatigue syndrome [let-
Learning Psychotherapy in a Biological Era. Disorders ter]. Fuchs; Krupp reply, Aug 296
Usdin, Jan 32 Lack of association between fluoxetine and sui- Classification
Locurto C: Sense and Nonsense About IQ: The cidality in bulimia nervosa. Wheadon, July DSM-III-R brief reactive psychosis among Air
Case for Uniqueness. Brink, May 176 235-241 Force recruits. Beighley, Aug 283-288
Myers WA (ed): New Techniques in the Psycho- Personality disorder diagnoses in patients with Clonidine
therapy of Older Patients. Blashko, July 259 bulimia nervosa: clinical correlates and Double-blind, placebo-controlled study of the
Rhodes LA: Emptying Beds: The Work of an changes with treatment. Ames-Frankel, Mar efficacy of transdermal clonidine in autism.
Emergency Psychiatric Unit. Stovall, June 90-96 Fankhauser, Mar 77-82
215 Preliminary investigation of the lifetime preva- Clozapine
Roy-Byrne PP, Cowley DS (eds): Benzodiaz- lence of anorexia and bulimia nervosa in pa- Clozapine-induced agranulocytosis in a native
epines in Clinical Practice: Risks and Ben- tients with obsessive compulsive disorder. American: HLA typing and further support
efits. Billings, Jan 31-32 Rubenstein, Sept 309-314 for an immune-mediated mechanism. Pfister,
Schlaifer C, Freeman L: Heart’s Work: Civil Symptom relapse in bulimia nervosa and obses- July 242-244
War Heroine and Champion of the Mentally sive compulsive disorder after treatment with Clozapine-induced myoclonic jerks and drop at-
Ill, Dorothea Lynde Dix. Surawicz, Nov 418 serotonin antagonists [letter]. Hollander, Jan tacks [letter]. Berman, Sept 329-330
Schwartz HJ, Silver A-L (eds): //Iness in the 28 Emergence of obsessive compulsive symptoms
Analyst. Mazza, Oct 382 Bupropion during treatment with clozapine. Baker, Dec
Scrignar CB: From Panic to Peace of Mind: Bupropion in the treatment of bipolar disorders: 439-442
Overcoming Panic and Agoraphobia. Bill- the same old story? Fogelson, Dec 443-446 Clozapine treatment of psychosis in Parkinson’s
ings, Aug 297-298 Catatonia associated with bupropion treatment disease: a report of five consecutive cases.
Serafica FC, Schwebel AI, Russell RK, Isaac [letter]. Jackson, June 210 Wolk, Oct 373-376
PD, Myers LB (eds): Mental Health of Ethnic Efficacy of bupropion in the winter depression: Granulocyte-macrophage colony-stimulating
Minorities. Surawicz, June 214 results of an open trial. Dilsaver, July 252- factor (GM-CSF) treatment of clozapine-in-
Smith GR Jr: Somatization Disorder in the 255 duced agranulocytosis: a case report. Barnas,
Medical Setting. Beitman, May 175 Falling backward in two elderly patients taking July 245-247
Socarides CW, Volkan VD (eds): The Homo- bupropion. Szuba, May 157-159 NMS and lethal catatonia [letter]. Weller;
sexualities: Reality, Fantasy, and the Arts. Fluoxetine and bupropion treatment of bipolar DasGupta reply, Aug 294-295
Levine, Oct 381 disorder, type II, associated with GAD [let- Restraint, seclusion and clozapine. Mallya, Nov
Socarides CW, Volkan VD (eds): The Homo- ter]. Novac, Feb 67 395-397
sexualities and the Therapeutic Process. Organic mental disorders associated with bupro- Should chronic treatment-refractory akathisia be
Stone, Oct 381-382 pion in three patients. Ames, Feb 53-55 an indication for the use of clozapine in
Stone MH: Unreviewed books [letter]. June 214 Capgras Syndrome schizophrenic patients? Levin, July 248-251
Stotland NL (ed): Psychiatric Aspects of Abor- Case of Capgras-Fregoli syndrome [letter]. Cognition Disorders
tion. Surawicz, May 175 Silva, Feb 67-68 Introduction and overview to clinical applica-
Stuber ML (ed): Children and AIDS. Thaggard, Carbamazepine tions of neuroSPECT in psychiatry. Schuckit,
Nov 419 Carbamazepine-associated thrombocytopenia Nov suppl 3-6
The Workgroup on Psychiatric Practice in the [letter]. Gordon; Tohen reply, Oct 378-379 Cognitive Therapy
Juvenile Court: Handbook of Psychiatric Do monoamine oxidase inhibitors alter carba- Pilot sequential study of cognitive therapy and
J Clin Psychiatry 53:12, December 1992
Subject Index: Volume 53
pharmacotherapy of atypical depression. [letter]. Coplan, Aug 293 lar problems. Roose, Sept supp! 25-31
Mercier, May 166-170 Double-blind comparison of paroxetine, imipra- Treatment of depression in special populations.
Comorbidity mine, and placebo in major depression. Reynolds, Sept suppl 45-53
Paraphilias, nonparaphilic sexual addictions, and Shrivastava, Feb suppl 48-51 Treatment of imipramine-resistant recurrent de-
social phobia [letter]. Golwyn, Sept 330 Double-blind, placebo-controlled study of par- pression, III: efficacy of monoamine oxidase
Personality disorder diagnoses in patients with oxetine in depressed outpatients. Kiev, Feb inhibitors. Thase, Jan 5-11
bulimia nervosa: clinical correlates and suppl 27-29 Two combined, multicenter double-blind studies
changes with treatment. Ames-Frankel, Mar Efficacy and safety of paroxetine compared with of paroxetine and doxepin in geriatric patients
90-96 placebo in outpatients with major depression. with major depression. Dunner, Feb suppl
Preliminary investigation of the lifetime preva- Rickels, Feb suppl 30-32 57-60
lence of anorexia and bulimia nervosa in pa- Efficacy and side effects of methylphenidate for Use of fluoxetine in depression associated with
tients with obsessive compulsive disorder. poststroke depression. Lazarus, Dec 00-00 anabolic steroid withdrawal: a case series.
Rubenstein, Sept 309-314 Introduction. Current perspectives on panic dis- Malone Jr, Apr 130-132
Prevalence of personality disorders in 210 order and major depression. Hirschfeld, Mar Dexamethasone
women with eating disorders. Herzog, May suppl 3-4 Dexamethasone for the treatment of depression
147-152 Introduction. Issues in the treatment of major [letter]. Coplan, Aug 293
Psychiatric comorbidity and suicidality among depression: selection, efficacy, and safety. Diagnosis
intravenous drug users. Dinwiddie, Oct 364— Blazer, Sept supp! 3-4 Comparison of diagnostic criteria for neuroleptic
369 Long-term clinical management of depressive malignant syndrome. Gurrera, Feb 56-62
Simultaneous major depression and panic disor- disorders. Burrows, Mar suppl 32-35 Diagnosis and treatment of insomnia and risks
der: treatment with electroconvulsive therapy. Long-term treatments of recurrent depressive associated with lack of treatment. Nino-
Figiel, Jan 12-15 disorders. Thase, Sept supp! 32-44 Murcia, Dec suppl 43-47
Treating the depressed patient with cardiovascu- Methylphenidate as a treatment for depression in Diagnostic confusion in treatment-refractory
lar problems. Roose, Sept suppl 25-31 acquired immunodeficiency syndrome: an n- psychotic patients. Smith, June 197-200
Continuation Treatment of-1 trial. White, May 153-156 DSM-III-R brief reactive psychosis among Air
Long-term clinical management of depressive Neurochemical alterations of serotonergic neuro- Force recruits. Beighley, Aug 283-288
disorders. Burrows, Mar suppl 32-35 nal systems in depression. Risch, Oct suppl Epidemiology and differential diagnosis of ob-
Corrections 3-7 sessive compulsive disorder. Rasmussen, Apr
Depressiun and cerebral stroke. Catapano, 1990 Novel selective serotonin reuptake inhibitors, suppl 4-10
Sept suppl 9-12; Notice to the readers, Aug part I. Mar Acapemic Hicuuicurs 107—112 Examination of syndromal validity and diagnos-
293 Paroxetine in major depression a double-blind tic subtypes in social phobia and panic disor-
Crohn’s Disease trial with imipramine and placebo. Cohn, Feb der. Gelernter, Jan 23-27
Bipolar disorder and Crohn’s disease [letter]. supp! 52-56 Factitious disorders with psychological symp-
Dommisse, Jan 29 Paroxetine in the treatment of depression: a toms. Popli, Sept 315-318
Cyproheptadine comparison with imipramine and placebo. “Gedankenlautwerden” and datura intoxication
Fluoxetine-induced yawning and anorgasmia re- Feighner, Feb suppl 44-47 [letter]. Goates, Apr 137
versed by cyproheptadine treatment [letter]. Paroxetine versus placebo: a double-blind com- Misdiagnosed bipolar disorder in adolescents in
Cohen, May 174 parison in depressed patients. Claghorn, Dec a special educational school and ireatment
Datura 434-438 program. Isaac, Apr 133-136
“Gedankenlautwerden” and datura intoxication Pilot sequential study of cognitive therapy and Usefulness of screening EEGs in psychiatric in-
[letter]. Goates, Apr 137 pharmacotherapy of atypical depression. patients [letter]. Schwitzer; Warner reply,
de Clerambault’s Syndrome Mercier, May 166-170 Sept 327-328
de Clerambault’s syndrome [letter]. Vicente; Placebo-controlled trial of paroxetine in the Dosage
Giannini reply, Apr 138-139 treatment of major depression. Smith, Feb Optimal dose regimen for paroxetine. Dunner,
Delirium suppl 36-39 Feb suppl 21-26
Ofloxacin-induced delirium [letter]. Fennig, Apr Poor response to fluoxetine: underlying depres- Doxepin
137-138 sion, serotonergic overstimulation, or a Two combined, multicenter double-blind studies
Should psychostimulants be used to treat deliri- “therapeutic window”? Cain, Aug 272-277 of paroxetine and doxepin in geriatric patients
ous patients with depressed mood [letter]? Premenstrual exacerbation of depression: one with major depression. Dunner, Feb suppl
Levenson; Ahmed reply, Feb 69 process or two? Yonkers, Aug 289-292 57-60
Dementia see also Alzheimer’s Disease Recent developments in the acute somatic treat- Drug Administration Routes
Catatonia in a patient with AIDS-related demen- ment of major depression. Schatzberg, Mar Depot neuroleptic therapy: an underutilized
tia [letter]. Snyder, Nov 414 suppl 20-25 treatment option. Glazer, Dec 426-433
Comparison of SPECT applications in neurol- Safety and efficacy of paroxetine compared with Double-blind, placebo-controlled study of the
ogy and psychiatry. Devous, Nov suppl 13- placebo in a double-blind trial of depressed efficacy of transdermal clonidine in autism.
19 outpatients. Claghorn, Feb suppl 33-35 Fankhauser, Mar 77-82
Depression Serotonin activity in psychotic (delusional) ma- Use of low-dose intranasal midazolam to treat
Bupropion in the treatment of bipolar disorders: jor depression. Schatzberg, Oct suppl 52-55 panic disorder: a pilot study. Schweizer, Jan
the same old story? Fogelson, Dec 443-446 Should psychostimulants be used to treat deliri- 19-22
Case of baclofen-induced psychotic depression ous patients with depressed mood [letter]? Drug Dependence/Withdrawal
[letter]. Sommer, June 211-212 Levenson; Ahmed reply, Feb 69 Loperamide dependence [letter]. Hill, Dec 450
Clinical course of panic disorder and depression. Simultaneous major depression and panic disor- Drug Discontinuation
Keller, Mar suppi 5-8 der: treatment with electroconvulsive therapy. Loperamide dependence [letter]. Hill, Dec 450
Closing remarks. Current perspectives on panic Figiel, Jan 12-15 Medication discontinuation in panic disorder.
disorder and major depression. Hirschfeld, Six-week, double-blind trial of paroxetine, imip- Ballenger, Mar suppl 26-31
Mar suppl 36 ramine, and placebo in depressed outpatients. Drug Side Effects
Comparison or SPECT applications in neurol- Fabre, Feb suppl 40-43 Case of baclofen-induced psychotic depression
ogy and psychiatry. Devous Sr, Nov suppl Somatic therapy for major depressive disorder: [letter]. Sommer, June 211-212
13-19 selection of an antidepressant. Preskorn, Sept Disinhibition, amnestic reactions, and other ad-
Depression and cerebral stroke. Catapano, 1990 suppl 5-18 verse reactions secondary to triazolam: a re-
Sept supp! 9-12; Notice to the readers, Aug Suicide risk factors in depressive disorders and view of the literature. Rothschild, Dec suppl
293 in panic disorder. Fawcett, Mar suppl 9-13 69-79
Dexamethasone for the treatment of depression Treating the depressed patient with cardiovascu- Falling backward in two elderly patients taking
J Clin Psychiatry 53:12, December 1992
Subject Index: Volume 53
bupropion. Szuba, May 157-159 sive compulsive disorder. Rasmussen, Apr Fregoli Syndrome
Medical consequences of the selection of an anti- suppl 4-10 Case of Capgras-Fregoli syndrome [letter]. Silva,
depressant. Nierenberg, Sept suppl 19-24 New epidemiologic findings about insomnia and Feb 67-68
Parnate formulation change [letter]. Malen; its treatment. Balter, Dec suppl 34-39 Fregoli syndrome: an unusual appearance in fic-
Murabito reply, Sept 328-329 Epilepsy tion [letter]. Schneck, Mar 101
Drug Therapy Comparison of SPECT applications in neurol- Geriatric Psychiatry
Adjunctive treatment of manic agitation with lor- ogy and psychiatry. Devous Sr, Nov suppl Insomnia in the elderly. Monane, June suppl 23—
azepam versus haloperidol: a double-blind 13-19 28
study. Lenox, Feb 47-52 Paranoid psychosis, epidermoid tumor, and epi- Treatment of depression in special populations.
Fluoxetine-lithium treatment for kleptomania [let- lepsy: “symptomatic” psychosis or coinci- Reynolds III, Sept suppl 45-53
ter]. Burstein, Jan 28-29 dence [letter]? Weller, July 257-258 Two combined, multicenter double-blind studies
Imperfect drugs in an imperfect world [editorial]. Factitious Disorders of paroxetine and doxepin in geriatric patients
Gelenberg, Feb 39-40 Factitious disorders with psychological symp- with major depression. Dunner, Feb suppl
Methylphenidate as a treatment for depression in toms. Popli, Sept 315-318 57-60
acquired immunodeficiency syndrome: an n- Fluoxetine Gilles de la Tourette’s Syndrome
of-1 trial. White, May 153-156 Acute dystonia and fluoxetine [letter]. Black, Fluvoxamine-induced frontal lobe syndrome in a
Pharmacotherapy of obsessive compulsive disor- Sept 327 patient with comorbid Gilles de la Tourette’s
der. Goodman, Apr suppl 29-37 Akathisia, suicidality, and fluoxetine. Hamilton, syndrome and obsessive compulsive disorder
Pilot sequential study of cognitive therapy and Nov 401-406 [letter]. George; Hoehn-Saric reply, Oct 379-
pharmacotherapy of atypical depression. Clinical characteristics of trichotillomania and 380
Mercier, May 166-170 its response to fluoxetine. Winchel, Sept Sensory phenomena associated with Gilles de la
Possible trazodone potentiation of fluoxetine: a 304-308 Tourette's syndrome. Cohen, Sept 319-323
case series. Nierenberg, Mar 83-85 Does fluoxetine exacerbate Parkinson’s disease? Grief
Potassium supplementation in lithium patients: a Caley, Aug 278-282 Treatment of depression in special populations.
timely intervention or premature speculation? Fluoxetine and bupropion treatment of bipolar Reynolds III, Sept supp! 45-53
Jefferson, Oct 370-372 disorder, type II, associated with GAD [let- Haloperidol
Psychopharmacological screening criteria: APA ter]. Novac, Feb 67 Adjunctive treatment of manic agitation with lor-
committee on research on psychiatric treat- Fluoxetine and suicidality [letter]. Pearlman; azepam versus haloperidol: a double-blind
ments [special article]. Kane, June 184-196 Rothschild reply, July 256 study. Lenox, Feb 47-52
Treatments for panic disorder. Klerman, Mar Fluoxetine treatment of nonparaphilic sexual ad- High incidence of haloperidol decanoate injec-
supp! 14-19 dictions and paraphilias in men. Kafka, Oct tion site reactions [letter]. Reinke; Hamann
Trends in the pharmacologic treatment of insom- 351-358 reply, Nov 415-416
nia. Walsh, Dec suppl 10-17 Fluoxetine treatment of slow eating [letter]. Health Care
Usefulness of screening EEGs in psychiatric in- Galynker, Aug 295-296 If not now, when [editoria!}? Gelenberg, Aug
patients [letter]. Schwitzer; Warner reply, Sept Fluoxetine-induced sexual dysfunction and an 266
327-328 open trial of yohimbine. Jacobsen, Apr 119- Homicide
Dystonia 122 Suicidal and homicidal ideations emerging dur-
Acute dystonia and fluoxetine [letter]. Black, Fluoxetine-induced yawning and anorgasmia re- ing a placebo period [letter]. Dominguez,
Sept 327 versed by cyproheptadine treatment [letter]. May 171
Eating Disorders see also Anorexia Nervosa; Cohen, May 174 Hormones
Bulimia Fluoxetine-lithium treatment for kleptomania Oral contraceptives and panic disorder. Deci,
Dangerous driving and eating disorders [letter]. [letter]. Burstein, Jan 28-29 May 163-165
Gupta, Nov 416 Lack of association between fluoxetine and sui- Human Immunodeficiency Virus
Fluoxetine treatment of slow eating [letter]. cidality in bulimia nervosa. Wheadon, July HIV-related psychosis [letter]. El-Mallakh, Aug
Galynker, Aug 295-296 235-241 293-294
Prevalence of personality disorders in 210 Poor response to fluoxetine: underlying depres- Hypertension
women with eating disorders. Herzog, May sion, serotonergic overstimulation, or a Is tranylcypromine really metabolized to am-
147-152 “therapeutic window”? Cain, Aug 272-277 phetamine [letter]? Jefferson; Zajecka reply,
Editorials Possible trazodone potentiation of fluoxetine: a Dec 450-451
If not now, when [editorial]? Gelenberg, Aug 266 case series. Nierenberg, Mar 83-85 Imipramine
Imperfect drugs in an imperfect world [editorial]. Ratio of plasma fluoxetine to norfluoxetine con- Double-blind comparison of paroxetine, imipra-
Gelenberg, Feb 39-40 centrations and associated sedation. Keck Jr, mine, and placebo in major depression.
In memoriam: William W.K. Zung, 1929-1992 Apr 127-129 Shrivastava, Feb suppl 48-51
[editorial]. Brodie, June 182-183 Single-dose fluoxetine in management of pre- Paroxetine in major depression: a double-blind
To all a good year [editorial]. Gelenberg Dec menstrual syndrome [letter]. Daamen, June trial with imipramine and placebo. Cchn, Feb
424-425 210-211 suppl 52-56
EEG see Electroencephalography Suicidal and homicidal ideations emerging dur- Paroxetine in the treatment of depression: a com-
Electroconvulsive Therapy ing a placebo period [letter]. Dominguez, parison with imipramine and placebo.
Simultaneous major depression and panic disor- May 171 Feighner, Feb suppl 44-47
der: treatment with electroconvulsive therapy. Suicidality and fluoxetine revisited [letter]. Six-week, double-blind trial of paroxetine, imip-
Figiel, Jan 12-15 Masand; Fava reply, Mar 102-103 ramine, and placebo in depressed outpatients.
Symptomatic predictors of ECT response in Treatment of fluoxetine-induced anorgasmia Fabre, Feb suppl 40-43
medication-nonresponsive manic patients. with amantadine [letter]. Balogh, June 212- Treatment of imipramine-resistant recurrent de-
Schnur, Feb 63-66 213 pression, III: efficacy of monoamine oxidase
Electroencephalography Use of fluoxetine in depression associated with inhibitors. Thase, Jan S—11
Usefulness of screening EEGs in psychiatric in- anabolic steroid withdrawal: a case series. Injections
patients [letter]. Schwitzer,; Warner reply, Sept Malone Jr, Apr 130-132 High incidence of haloperidol decanoate injec-
327-328 Fluvoxamine tion site reactions [letter]. Reinke; Hamann
Enalapril Fluvoxamine-induced frontal lobe syndrome in a reply, Nov 415-416
Effect of enalapril on serum lithium levels in patient with comorbid Gilles de la Tourette’s Injection site reactions [letter]. Hay, July 256
healthy men. DasGupta, Nov 398-400 syndrome and obsessive compulsive disorder Insomnia
Epidemiology [letter]. George; Hoehn-Saric reply, Oct 379- Diagnosis and treatment of insomnia and risks
Epidemiology and differential diagnosis of obses- 380 associated with lack of treatment. Nino-
J Clin Psychiatry 53:12, December 1992
Subject Index: Volume 53
Murcia, Dec suppl 43-47 process or two? Yonkers, Aug 289-292 Fluoxetine treatment of slow eating [letter].
New epidemiologic findings about insomnia and Methylphenidate Galynker, Aug 295-296
its treatment. Balter, Dec suppl 34-39 Efficacy and side effects of methylphenidate for Integrated approach to treatment of obsessive
Pharmacist's role in the recognition and manage- poststroke depression. Lazarus, Dec 447-449 compulsive disorder. Greist, Apr suppl 38-
ment of insomnia. Wincor, Dec suppl 80-83 Methylphenidate and seizure frequency in brain 41
Trends in the pharmacologic treatment of in- injured patients with seizure disorders. Introduction. Obsessive compulsive disorder:
somnia. Walsh, Dec suppl 10-17 Wroblewski, Mar 86-89 integrating theory and practice. Goodman,
Intermetamorphosis Syndrome Methylphenidate as a treatment for depression in Apr suppl 3
Intermetamorphosis syndrome [letter]. De Leon, acquired immunodeficiency syndrome: an n- Pharmacotherapy of obsessive compulsive dis-
Jan 29-30 of-1 trial. White, May 153-156 order. Goodman, Apr supp] 29-37
Journal of Clinical Psychiatry Midazolam Preliminary investigation of the lifetime preva-
If not now, when [editorial]? Gelenberg, Aug Use of low-dose intranasal midazolam to treat lence of anorexia and bulimia nervosa in pa-
266 panic disorder: a pilot study. Schweizer, Jan tients with obsessive compulsive disorder.
To all a good year [editorial]. Gelenberg Dec 19-22 Rubenstein, Sept 309-314
424-425 Monoamine Oxidase Inhibitors Serotonergic antidepressants and their efficacy
Kleptomania Do monoamine oxidase inhibitors alter carba- in obsessive compulsive disorder.
Fluoxetine-lithium treatment for kleptomania mazepine blood levels [letter]? Jefferson, July Dominguez, Oct suppl 56-59
[letter]. Burstein, Jan 28-29 258 Serotonin hypothesis of obsessive compulsive
L-Triiodothyronine Is tranylcypromine really metabolized to am- disorder: implications of pharmacologic
T3 augmentation of antidepressant treatment in phetamine [letter]? Jefferson; Zajecka reply, challenge studies. Barr, Apr supp! 17-28
T4-replaced thyroid patients. Cooke, Jan 16— Dec 450-451 Symptom relapse in bulimia nervosa and obses-
18 Treatment of imipramine-resistant recurrent de- sive compulsive disorder after treatment with
Lithium pression, III: efficacy of monoamine oxidase serotonin antagonists [letter]. Hollander, Jan
Effect of enalapril on serum lithium levels in inhibitors. Thase, Jan 5-11 28
healthy men. DasGupta, Nov 398-400 Mood Treatment outcome of obsessive compulsive
Fluoxetine-lithium treatment for kleptomania Head injury and mood disturbance [letter]. disorder with comorbid social phobia.
[letter]. Burstein, Jan 28-29 Miller, May 171-172 Carrasco, Nov 387-391
Potassium supplementation in lithium patients: a Munchausen Syndrome Ofloxacin
timely intervention or premature speculation? Factitious disorders with psychological symp- Ofloxacin-induced delirium [letter]. Fennig,
Jefferson, Oct 370-372 toms. Popli, Sept 315-318 Apr 137-138
Loperamide Myoclonus Organic Mental Disorders
Loperamide dependence [letter]. Hill, Dec 450 Clozapine-induced myoclonic jerks and drop at- Organic mental disorders associated with bu-
Lorazepam tacks [letter]. Berman, Sept 329-330 propion in three patients. Ames, Feb 53-55
Adjunctive treatment of manic agitation with Nadolol Treatment of depression in special populations.
lorazepam versus haloperidol: a double-blind Nadolol to treat aggression and psychiatric Reynolds Ill, Sept suppl 45-53
study. Lenox, Feb 47-52 symptomatology in chronic psychiatric inpa- Tricyclic antidepressant triggers mania in pa-
AIDS-related psychosis with catatonia respond- tients: a double-blind, placebo-controlled tient with organic affective disorder [letter].
ing to low-dose lorazepam [letter]. study. Ratey, Feb 41-46 Santos, Oct 377-378
Scamvougeras, Nov 414-415 Neuroleptic Malignant Syndrome Panic
Catatonia in a patient with AIDS-related demen- Comparison of diagnostic criteria for neuroleptic Clinical course of panic disorder and depres-
tia [letter]. Snyder, Nov 414 malignant syndrome. Gurrera, Feb 56-62 sion. Keller, Mar suppl 5-8
NMS and lethal catatonia [letter]. Weller; NMS and lethal catatonia [letter]. Weller; Closing remarks. Current perspectives on panic
DasGupta reply, Aug 294-295 DasGupta reply, Aug 294-295 disorder and major depression. Hirschfeld,
Lupus Anticoagulant Neuroleptics see also specific drugs Mar suppl 36
Phenothiazine-induced lupus anticoagulant [let- Depot neuroleptic therapy: an underutilized Effects of pregnancy on preexisting panic disor-
ter]. Kaslow, Mar 103-104 treatment option. Glazer, Dec 426-433 der. Villeponteaux, June 201-203
Maintenance Treatment see also Continua- Response of negative symptoms of schizophre- Examination of syndromal validity and diag-
tion Treatment nia to neuroleptic treatment. Serban, July nostic subtypes in social phobia and panic
Long-term treatments of recurrent depressive 229-234 disorder. Gelernter, Jan 23-27
disorders. Thase, Sept suppl 32-44 Nifedipine Fluoxetine treatment of slow eating [letter].
Mania Nifedipine and nonresponse to antidepressants Galynker, Aug 295-296
Adjunctive treatment of manic agitation with {letter]. Fadden; Nierenberg reply, Nov 416— Introduction. Current perspectives on panic dis-
lorazepam versus haloperidol: a double-blind 417 order and major depression. Hirschfeld, Mar
study. Lenox, Feb 47-52 Obsessive Compulsive Disorder suppl 34
Bupropion in the treatment of bipolar disorders: Childhood obsessive compulsive disorder. Medication discontinuation in panic disorder.
the same old story? Fogelson, Dec 443-446 Rapoport, Apr suppl 11-16 Ballenger, Mar suppl 26-31
HIV-related psychosis [letter]. El-Mallakh, Aug Clinical characteristics of trichotillomania and Night terrors in aduits: phenomenology and re-
293-294 its response to fluoxetine. Winchel, Sept lationship to psychopathology. Llorente, Nov
Mania self-induced with cough syrup [letter]. 304-308 392-394
Mendez, May 173-174 Comparison of SPECT applications in neurol- Oral contraceptives and panic disorder. Deci,
Symptomatic predictors of ECT response in ogy and psychiatry. Devous Sr, Nov suppl May 163-165
medication-nonresponsive manic patients. 13-19 Simultaneous major depression and panic disor-
Schnur, Feb 63-66 Emergence of obsessive compulsive symptoms der: treatment with electroconvulsive ther-
Tricyclic antidepressant triggers mania in patient during treatment with clozapine. Baker, Dec apy. Figiel, Jan 12-15
with organic affective disorder [letter]. 439-442 Suicide risk factors in depressive disorders and
Santos, Oct 377-378 Epidemiology and differential diagnosis of ob- in panic disorder. Fawcett, Mar suppl 9-13
Medical Illness sessive compulsive disorder. Rasmussen, Apr Treatments for panic disorder. Klerman, Mar
Psychiatrists and physical illness: clarification suppl 4-10 suppl 14-19
[letter]. DuRand, June 213 Fluvoxamine-induced frontal lobe syndrome in a Use of low-dose intranasal midazolam to treat
Sleep disorders in the medically ill patient. patient with comorbid Gilles de la Tourette’s panic disorder: a pilot study. Schweizer, Jan
Moran, June suppl 29-36 syndrome and obsessive compulsive disorder 19-22
Menstrual Cycle [letter]. George; Hoehn-Saric reply, Oct 379- Parkinson’s Disease
Premenstrual exacerbation of depression: one 380 Clozapine treatment of psychosis in Parkinson’s
J Clin Psychiatry 53:12, December 1992
Subject Index: Volume 53
disease: a report of five consecutive cases. social phobia [letter]. Golwyn, Sept 330 Psychotherapy
Wolk, Oct 373-376 Treatment outcome of obsessive compulsive Nonpharmacologic treatments of insomnia.
Does fluoxetine exacerbate Parkinson’s disease? disorder with comorbid social phobia. Bootzin, June suppl 37-41
Caley, Aug 278-282 Carrasco, Nov 387-391 Restraint, Physical
Parnate Phototherapy Restraint, seclusion and clozapine. Mallya, Nov
Parnate formulation change [letter]. Malen; Gradual versus rapid dawn simulation treat- 395-397
Murabito reply, Sept 328-329 ment of winter depression. Avery, Oct 359- Schizophrenia
Paroxetine 363 “Gedankenlautwerden” and datura intoxication
Conclusions. A clinical profile of paroxetine: a Pick’s Disease [letter]. Goates, Apr 137
novel selective serotonin reuptake inhibitor Case of early-onset Pick’s disease [letter]. Introduction and overview to clinical applica-
(SSRI). Boyer, Feb supp! 67-68 Stewart, Oct 380 tions of neuroSPECT in psychiatry. Schuckit,
Double-blind comparison of paroxetine, imipra- Pimozide Nov suppl 3-6
mine, and placebo in major depression. Low-dose pimozide augmentation of serotonin Regional cerebral blood flow imaging with
Shrivastava, Feb suppl 48-51 reuptake blockers in the treatment of tricho- SPECT in psychiatric disease: focus on
Double-blind, placebo-controlled study of parox- tillomania. Stein, Apr 123-126 schizophrenia, anxiety disorders, and sub-
etine in depressed outpatients. Kiev, Feb suppl New possible indications of pimozide [letter]. stance abuse. Woods, Nov suppl 20--25
27-29 Iruela; Opler reply, May 172-173 Response of negative symptoms of schizophre-
Efficacy and safety of paroxetine compared with Postpartum Psychosis nia to neuroleptic treatment. Serban, July
placebo in outpatients with major depression. Response to sleep deprivation in three women 229-234
Rickels, Feb suppl 30-32 with postpartum psychosis. Strouse, June Should chronic treatment-refractory akathisia be
Optimal dose regimen for paroxetine. Dunner, 204-206 an indication for the use of clozapine in
Feb suppl 21-26 Posttraumatic Stress Disorder schizophrenic patients? Levin, July 248-251
Overview of paroxetine. Boyer, Feb suppl 3-6 Psychophysiologic response during script- Seasonal Affective Disorder
Paroxetine in major depression: a double-blind driven imagery as an outcome measure in Efficacy of bupropion in winter depression: re-
trial with imipramine and placebo. Cohn, Feb posttraumatic stress disorder. Shalev, Sept sults of an open trial. Dilsaver, July 252-255
suppl 52-56 324-326 Gradual versus rapid dawn simulation treatment
Paroxetine in the treatment of depression: a com- Potassium of winter depression. Avery, Oct 359-363
parison with imipramine and placebo. Potassium supplementation in lithium patients: Seclusion
Feighner, Feb suppl 44-47 a timely intervention or premature specula- Restraint, seclusion and clozapine. Mallya, Nov
Paroxetine versus placebo: a double-blind com- tion? Jefferson, Oct 370-372 395-397
parison in depressed patients. Claghorn, Dec Prediction Sedative Hypnotics
434-438 Symptomatic predictors of ECT response in Nonsedating treatments for Alzheimer’s patients
Pharmacologic profile of paroxetine, a new se- medication-nonresponsive manic patients. with behavioral problems [letter]. Hawkins;
lective serotonin reuptake inhibitor. Tulloch, Schnur, Feb 63-66 Goad reply, Mar 101-102
Feb suppl 7-12 Pregnancy Seizures
Placebo-controlled trial of paroxetine in the treat- Effects of pregnancy on preexisting panic dis- Clozapine-induced myoclonic jerks and drop at-
ment of major depression. Smith, Feb suppl order. Villeponteaux, June 201-203 tacks [letter]. Berman, Sept 329-330
36-39 Premenstrual Syndrome Methylphenidate and seizure frequency in brain
Safety and efficacy of paroxetine compared with Single-dose fluoxetine in management of pre- injured patients with seizure disorders.
placebo in a double-blind trial of depressed menstrual syndrome [letter]. Daamen, June Wroblewski, Mar 86-89
outpatients. Claghorn, Feb suppl 33-35 210-211 Tricyclic antidepressant-induced seizures and
Safety profile of paroxetine. Boyer, Feb suppl Primary Care plasma drug concentration. Preskorn, May
61-66 Proper use of sleeping pills in the primary care 160-162
Six-week, double-blind trial of paroxetine, imip- setting. Dement, Dec supp! 50-56 Serotonin
ramine, and placebo in depressed outpatients. Psychiatrists Aggression, suicidality, and serotonin. Linnoila,
Fabre, Feb suppl 40-43 In memoriam: William W.K. Zung, 1929-1992 Oct suppl 46-51
Two combined, multicenter double-blind studies [editorial]. Brodie, June 182-183 Basic advances in serotonin pharmacology.
of paroxetine and doxepin in geriatric patients Psychiatrists and physical illness: ciarification Fuller, Oct supp! 36-45
with major depression. Dunner, Feb suppl 57— [letter]. DuRand, June 213 Low-dose pimozide augmentation of serotonin
Psychosis see also specific diagnoses reuptake blockers in the treatment of tricho-
Personality Disorders AIDS-related psychosis with catatonia respond- tillomania. Stein, Apr 123-126
Personality and clinical characteristics in patients ing to low-dose lorazepam [letter]. Molecular biology of serotonin receptors.
with trichotillomania. Christenson, Nov 407— Scamvougeras, Nov 414-415 Harrington, Oct suppl 8-27
413 Clozapine treatment of psychosis in Neurochemical alterations of serotonergic neu-
Personality disorder diagnoses in patients with Parkinson’s disease: a report of five con- ronal systems in depression. Risch, Oct suppl
bulimia nervosa: clinical correlates and secutive cases. Wolk, Oct 373-376 3-7
changes with treatment. Ames-Frankel, Mar Diagnostic confusion in treatment-refractory New directions in antidepressant therapy: a
90-96 psychotic patients. Smith, June 197-200 review of sertraline, a unique serotonin
Prevalence of personality disorders in 210 DSM-III-R brief reactive psychosis among Air reuptake inhibitor. Sept Acapemic Hicuuicuts
women with eating disorders. Herzog, May Force recruits. Beighley, Aug 283-288 333-340
147-152 HIV-related psychosis [letter]. El-Mallakh, Aug Novel selective serotonin reuptake inhibitors,
Pharmacists 293-294 part I. Mar Acapemic Hicuuicuts 107-112
Pharmacist's role in the recognition and manage- New possible indications of pimozide [letter]. Novel selective serotonin reuptake inhibitors,
ment of insomnia. Wincor, Dec suppl 80-83 Iruela; Opler reply, May 172-173 part II. June Acapemic Hicuuicuts 216-221
Pharmacotherapy see Drug Therapy Paranoid psychosis, epidermoid tumor, and epi- Overview of paroxetine. Boyer, Feb suppl 3-6
Phenothiazines lepsy: “symptomatic” psychosis or coinci- Pharmacokinetics of the selective serotonin re-
Phenothiazine-induced lupus anticoagulant [let- dence [letter]? Weller, July 257-258 uptake inhibitors. DeVane, Feb suppl 13-20
ter]. Kaslow, Mar 103-104 Serotonin activity in psychotic (delusional) ma- Pharmacologic profile of paroxetine, a new se-
Phobias jor depression. Schatzberg, Oct suppl 52-55 lective serotonin reuptake inhibitor. Tulloch,
Examination of syndromal validity and diagnos- Psychostimulants Feb suppl 7-12
tic subtypes in social phobia and panic disor- Should psychostimulants be used to treat deliri- Pharmacotherapy of obsessive compulsive dis-
der. Gelernter, Jan 23-27 ous patients with depressed mood [letter]? order. Goodman, Apr suppl 29-37
Paraphilias, nonparaphilic sexual addictions, and Levenson; Ahmed reply, Feb 69 Poor response to fluoxetine: underlying depres-
J Clin Psychiatry 53:12, December 1992
Subject Index: Volume 53
sion, serotonergic overstimulation, or a schizophrenia, anxiety disorders, and sub- May 171
“therapeutic window”? Cain, Aug 272-277 stance abuse. Woods, Nov suppl 20-25 Suicidality and fluoxetine revisited [letter].
Serotonergic antidepressants and their efficacy Sleep Masand; Fava reply, Mar 102-103
in obsessive compulsive disorder. Clinical uses and advantages of low-deses of Suicide risk factors in depressive disorders and
Dominguez, Oct suppl 56-59 benzodiazepine hypnotics. Vogel, June suppl in panic disorder. Fawcett, Mar suppl 9-13
Serotonergic medications for sexual obsessions, 19-22 Systemic Lupus Erythematosus
sexual addictions, and paraphilias. Stein, Aug Epidemiology and occurrence of insomnia. Phenothiazine-induced lupus anticoagulant [let-
267-271 Rosekind, June supp! 4-6 ter]. Kaslow, Mar 103-104
Serotonin activity in psychotic (delusional) ma- Insomnia in the elderly. Monane, June suppl 23— Thrombocytopenia
jor depression. Schatzberg, Oct suppl 52-55 28 Carbamazepine-associated thrombocytopenia
Serotonin hypothesis of obsessive compulsive Introduction. Current strategies in the treatment [letter]. Gordon; Tohen reply, Oct 378-379
disorder: implications of pharmacologic chal- of insomnia. Mendelson, June suppl 3 Thyroid Disorders
lenge studies. Barr, Apr supp! 17-28 Issues in the use of benzodiazepine therapy. T3 augmentation of antidepressant treatment in
Symptom relapse in bulimia nervosa and obses- Roth, June suppl 14-18 T4-replaced thyroid patients. Cooke, Jan 16-
sive compulsive disorder after treatment with Night terrors in adults: phenomenology and rela- 18
serotonin antagonists [letter]. Hollander, Jan tionship to psychopathology. Llorente, Nov Thyroxine
28 392-394 T3 augmentation of antidepressant treatment in
Treatment outcome of obsessive compulsive dis- Nonpharmacologic treatments of insomnia. T4-replaced thyroid patients. Cooke, Jan 16—-
order with comorbid social phobia. Carrasco, Bootzin, June suppl 37-41 18
Nov 387-391 Problem-solving approach to the treatment of in- Tranylcypromine
Yohimbine treatment of sexual side effects in- somnia: selected case histories. Trilling, June Is tranylcypromine really metabolized to am-
duced by serotonin reuptake blockers. Hol- suppl 42-45 phetamine [letter]? Jefferson; Zajecka reply,
lander, June 207-209 Proper use of sleeping pills in the primary care Dec 450-451
Sertraline setting. Dement, Dec suppl 50-56 Parnate formulation change [letter]. Malen;
New directions in antidepressant therapy: a Ratio of plasma fluoxetine to norfluoxetine con- Murabito reply, Sept 328-329
review of sertraline, a unique serotonin centrations and associated sedation. Keck Jr, Trazodone
reuptake inhibitor. Sept Acapemic Hicuticurs Apr 127-129 Possible trazodone potentiation of fluoxetine: a
333-340 Response to sleep deprivation in three women case series. Nierenberg, Mar 83--85
Sexual Disorders with postpartum psychosis. Strouse, June Triazolam
Comparative study of nonparaphilic sexual ad- 204-206 Comparative clinical profiles of triazolam versus
dictions and paraphilias in men. Kafka, Oct Sleep disorders in the medically ill patient. other shorter-acting hypnotics. Jonas, Dec
345-350 Moran, June suppl 29-36 supp! 19-31
Fluoxetine treatment of nonparaphilic sexual ad- Social Phobia see Phobias Disinhibition, amnestic reactions, and other ad-
dictions and paraphilias in men. Kafka, Oct Steroids verse reactions secondary to triazolam: a re-
351-358 Anabolic steroid use among substance abusers view of the literature. Rothschild, Dec suppl
Paraphilias, nonparaphilic sexual addictions, and in treatment. Clancy, Mar 97-100 69-79
social phobia [letter]. Golwyn, Sept 330 Use of fluoxetine in depression associated with Review of triazolam data. Klett, Dec suppl 61-
Serotonergic medications for sexual obsessions, anabolic steroid withdrawal: a case series. 67
sexual addictions, and paraphilias. Stein, Aug Malone Jr, Apr 130—132 Trichotillomania
267-271 Substance Abuse Clinical characteristics of trichoiillomania and
Sexual Dysfunction Anabolic steroid use among substance abusers its response to fluoxetine. Winchel, Sept
Fluoxetine-induced sexual dysfunction and an in treatment. Clancy, Mar 97—100 304-308
open trial of yohimbine. Jacobsen, Apr 119- Introduction and overview to clinical applica- Low-dose pimozide augmentation of serotonin
122 tions of neuroSPECT in psychiatry. Schuckit, reuptake blockers in the treatment of trichotil-
Fluoxetine-induced yawning and anorgasmia re- Nov suppl 3-6 lomania. Stein, Apr 123-126
versed by cyproheptadine treatment [letter]. Mania self-induced with cough syrup [letter]. Personality and clinical characteristics in pa-
Cohen, May 174 Mendez, May 173-174 tients with trichotillomania. Christenson, Nov
Treatment of fluoxetine-induced anorgasmia Psychiatric comorbidity and suicidality among 407-413
with amantadine [letter]. Balogh, June 212- intravenous drug users. Dinwiddie, Oct 364— Tryptophan
213 369 Acute tryptophan depletion: a method of study-
Yohimbine treatment of sexual side effects in- Regional cerebral blood flow imaging with ing antidepressant action. Miller, Oct suppl
duced by serotonin reuptake blockers. Hol- SPECT in psychiatric disease: focus on 28-35
lander, June 207—209 schizophrenia, anxiety disorders, and sub- Violence
Single Photon Emission Computed Tomogra- stance abuse. Woods, Nov suppl 20-25 Aggression, suicidality, and serotonin. Linnoila,
phy Suicide Oct suppl 46-51
Brain SPECT imaging and psychiatry. Van Aggression, suicidality, and serotonin. Linnoila, Nadolol to treat aggression and psychiatric
Heertum, Nov suppl 7-12 Oct suppl 46-51 symptomatclogy in chronic psychiatric inpa-
Comparison of SPECT applications in neurol- Akathisia, suicidality, and fluoxetine. Hamilton, tients: a double-blind, placebo-controlled
ogy and psychiatry. Devous Sr, Nov suppl Nov 401-406 study. Ratey, Feb 41-46
13-19 Fluoxetine and suicidality [letter]. Pearlman; Vitamins
Current and future applications of SPECT in Rothschild reply, July 256-256 Bipolar disorder and Crohn’s disease [letter].
clinical psychiatry. Volkow, Nov 26-28 Lack of association between fluoxetine and sui- Dommisse, Jan 29
Introduction and overview to clinical applica- cidality in bulimia nervosa. Wheadon, July Yohimbine
tions of neuroSPECT in psychiatry. Schuckit, 235-241 Fluoxetine-induced sexual dysfunction and an
‘Nov suppl 3-6 Psychiatric comorbidity and suicidality among open trial of yohimbine. Jacobsen, Apr 119-
Neuroreceptor imaging with SPECT. Innis, Nov intravenous drug users. Dinwiddie, Oct 364— 122
suppl 29-34 369 Yohimbine treatment of sexual side effects in-
Regional cerebral blood flow imaging with Suicidal and homicidal ideations emerging dur- duced by serotonin reuptake blockers. Hol-
SPECT in psychiatric disease: focus on ing a placebo period [letter]. Dominguez, lander, June 207-209
J Clin Psychiatry 53:12, December 1992
Journal of Clinical Psychiatry
Author Index to Volume 53: January 1992 Through December 1992
Abassian M see Lazarus LW Jr. DSM-III-R brief reactive psychosis Carrasco JL see Hollander E
Ahmed I. Reply to Levenson JA: Should among Air Force recruits. Aug 283-288 Casper RC. Review of Yates A: Compulsive
psychostimulants be used to treat delirious Beitman BD. Review of Smith GR Jr: Somati- Exercise and the Eating Disorders: Toward
patients with depressed mood [letter]? Feb 69 zation Disorder in the Medical Setting. May an Integrated Theory of Activity. Apr 141
Amado H. Review of Winokur G: Mania and 175 Catapano F, Galderisi S. Depression and cere-
Depression: A Classification of Syndrome Bemporad JR see Ratey JJ bral stroke. 1990 Sept suppl 9-12. Notice to
and Disease. Dec 452 Berman I, Zalma A, DuRand CJ, Green AI. the readers, Aug 293
Ames D, Wirshing WC, Szuba MP. Organic Clozapine-induced myoclonic jerks and drop Chang SS see Gurrera RJ
mental disorders associated with bupropion attacks [letter]. Sept 329-330 Charney DS see Barr LC; Miller HL
in three patients. Feb 53-55 Bernet W. Review of The Workgroup on Psy- Chengappa KNR see Baker RW; Levin H
Ames-Frankel J, Devlin MJ, Walsh BT, chiatric Practice in the Juvenile Court: Hand- Chernoff-Clementz E see Christenson GA
Strasser TJ, Sadik C, Oldham JM, Roose book of Psychiatric Practice in the Juvenile Christ MAG see Baker RW
SP. Personality disorder diagnoses in patients Court. Sept 331 Christensen JF see White JC
with bulimia nervosa: clinical correlates and Billings CK. Review of Roy-Byrme PP, Cowley Christenson GA, Chernoff-Clementz E,
changes with treatment. Mar 90-96 DS (eds): Benzodiazepines in Clinical Prac- Clementz BA. Personality and clinical char-
Amsterdam J see Rickels K tice: Risks and Benefits. Jan 31-32 acteristics in patients with trichotillomania.
Ancill RJ see Smith GN Billings CK. Review of Scrignar CB (eds): Nov 407-413
Anthony DT see Stein DJ From Panic to Peace of Mind: Overcoming Ciaranello RD see Harrington MA
Arana GW see Deci PA Panic and Agoraphobia. Aug 297-298 Claghorn JL. Safety and efficacy of paroxetine
Avery DH, Boite MAP, Cohen S, Millet MS. Black B, Uhde TW. Acute dystonia and fluoxe- compared with placebo in a double-blind trial
Gradual versus rapid dawn simulation treat- tine [letter]. Sept 327 ‘i of depressed outpatients. Feb suppl 33-35
ment of winter depression. Oct 359-363 Blashko CA. Review of Myers WA (ed): New Claghorn JL, Kiev A, Rickels K, Smith WT,
Baird JW see Baker RW Techniques in the Psychotherapy of Older Dunbar GC. Paroxetine versus placebo: a
Baker LA see Keller MB Patients. July 259 double-blind comparison in depressed pa-
Baker RW, Chengappa KNR, Baird JW, Blazer DG. Introduction. Issues in the treatment tients. Dec 434-438
Steingard S, Christ MAG, Schooler NR. of major depression: selection, efficacy, and Clancy GP, Yates WR. Anabolic steroid use
Emergence of obsessive compulsive symp- safety. Sept supp] 3-4 among substance abusers in treatment. Mar
toms during treatment with clozapine. Dec Blumhardt CL see Boyer WF; Shrivastava 97-100
439-442 RK Clary C see Rickels K; Schweizer E
Ballenger JC. Medication discontinuation in Bolte MAP see Avery DH Clementz BA see Christenson GA
panic disorder. Mar suppl 26-31 Bootzin RR, Perlis ML. Nonpharmacologic Cloninger CR see Dinwiddie SH
Ballenger JC see Santos AB; Villeponteaux treatments of insomnia. June suppl 37-41 Cohen AJ. Fluoxetine-induced yawning and
VA Boutros NN see Warner MD anorgasmia reversed by cyproheptadine treat-
Balogh S, Hendricks SE, Kang J. Treatment Boyer WF. Conclusions. A clinical profile of ment [letter]. May 174
of fluoxetine-induced anorgasmia wit aman- paroxetine: a novel selective serotonin reup- Cohen AJ, Leckman JF. Sensory phenomena
tadine [letter]. June 212-213 take inhibitor. Feb suppl 67-68 associated with Gilles de la Tourette's syn-
Balter MB, Uhlenhuth EH. New epidemiolog- Boyer WF, Blumhardt CL. Safety profile of drome. Sept 319-323
ic findings about insornnia and its treatment. paroxetine. Feb suppl 61-66 Cohen S see Avery DH
Dec suppl 34-39 Boyer WF, Feighner JP. Overview of paroxe- Cohn CK see Dunner DL
Barklage NE, Jefferson JW, Margolis D. Do tine. Feb suppl 3-6 Cohn JB, Wilcox CS. Paroxetine in major de-
monoamine oxidase inhibitors alter carba- Boyer WF see Feighner JP pression: a double-blind trial with imipramine
mazepine blood levels [letter]? July 258 Brink TL. Review of Locurto C: Sense and and placebo. Feb suppl 52-56
Barnas C, Zwierzina H, Hummer M, Nonsense About IQ: The Case for Unique- Cohn JB see Dunner DL
Sperner-Unterweger B, Stern A, ness. May 176 Cole JO see Kane JM; Nierenberg AA
Fleischhacker WW. Granulocyte-macroph- Brodie HKH. In memoriam: William W. K. Coleman BS see Jonas J
age colony-stimulating factor (GM-CSF) Zung, 1929-1992 [editorial]. June 182-183 Cooke RG, Joffe RT, Levitt AJ. T; augmenta-
treatment of clozapine-induced agranulocyto- Brown GR see Beighley PS Jr tion of antidepressant treatment in T,-
sis: a case report. July 245-247 Brown WA see Daamen MJ replaced thyroid patients. Jan 16-18
Barr LC, Goodman WK, Price LH, Burke M see Preskorn SH Coplan JD, Taylor L, Gorman JM. Dexam-
McDougle CJ, Charney DS. Serotonin hy- Burrows GD. Long-term clinical management ethasone for the treatment of depression [let-
pothesis of obsessive compulsive disorder: of depressive disorders. Mar suppl 32-35 ter]. Aug 293
implications of pharmacologic challenge Burstein A. Fluoxetine-lithium treatment for Creelman WL see Lenox RH
studies. Apr suppl 17-28 kleptomania [letter]. Jan 28-29 Cummings JL. Review of Becker RE,
Barr LC see Miller HL Bystritsky A see Fogelson DL Giacobini E (eds): Alzheimer’s Disease: Cur-
Battle AO. Review of Evangelista A: Dictio- Cain JW. Poor response to fluoxetine: underly- rent Research in Early Diagnosis. Mar 105
nary of Hypnotism. Mar 106 ing depression, serotonergic overstimulation, Currier MB see Llorente MD
Battle AO. Review of Exner JE Jr: The Ror- or a “therapeutic window”? Aug 272-277 Daamen MJ, Brown WA. Single-dose fluoxe-
schach: A Comprehensive System, Vol. 2: In- Caley CF, Friedman JH. Does fluoxetine ex- tine in management of premenstrual syn-
terpretation, 2nd Ed. Sept 331-332 acerbate Parkinson’s disease? Aug 278-282 drome [letter]. June 210-211
Bauer RM see Stewart JT Carrasco JL, Hollander E, Schneier FR, Daehler ML see Ratey JJ
Baxter LR Jr see Strouse TB Liebowitz MR. Treatment outcome of obses- Dalack GW see Roose SP
Beasley CM Jr see Wheadon DE sive compulsive disorder with comorbid so- DasGupta K, Jefferson JW, Kobak KA,
Beighley PS Jr, Brown GR, Thompson JW cial phobia. Nov 387-391 Greist JH. Effect of enalapril on serum
J Clin Psychiatry 53:12, December 1992
Author Index: Volume 53
lithium levels in healthy men. Nov 398-400 blind, placebo-controlled study of the effi- and obsessive compulsive disorder [letter
DasGupta K, Young A. Reply to Weller M: cacy of transdermal clonidine in autism. Mar with reply]. Oct 379
NMS and lethal catatonia [letter]. Aug 295 77-82 German ML see Fankhauser MP
DeCaria CM see Hollander E Fast GA see Preskorn SH Giannini AJ. Reply to Vicente YMR: de
De Leon OA. Intermetamorphosis syndrome Faustman WO see Miller LS Clerambault’s syndrome [letter]. Apr 139
[letter]. Jan 29-30 Fava M, Rosenbaum JF. Repiy to Masand P: Gilaberte I see Iruela LM
Dement WC. Proper use of sleeping pills in the Suicidality and fluoxetine revisited [letter]. Glass L see Nierenberg AA
primary care setting. Dec suppl 50-56 Mar 103 Glaudin V see Smith WT
DeVane CL. Pharmacokinetics of the selective Fawcett J. Suicide risk factors in depressive Glazer WM, Kane JM. Depot neuroleptic
serotonin reuptake inhibitors. Feb suppl 13- disorders and in panic disorder. Mar suppl 9- therapy: an underutilized treatment option.
20 13 Dec 426-433
Deci PA, Lydiard RB, Santos AB, Arana Fawcett J see Lazarus LW Goad DL. Reply to Hawkins JW: Nonsedating
GW. Oral contraceptives and panic disorder. Faweett JA see Zajecka JM treatments for Alzheimer’s patients with be-
May 163-165 Feighner JP, Boyer WF. Paroxetine in the havioral problems [letter]. Mar 102
Delgado PL see Miller HL treatment of depression: a comparison with Goates MG, Escobar JI. “Gedankenlautwerden”
Del Medico VJ see Dilsaver SC imipramine and placebo. Feb suppl 44-47 and datura intoxication [letter]. Apr 137
Deustch SI see Kaslow KA Feighner JP see Boyer WF; Dunner DL Gold DD Jr. Review of Addonizio G, Susinan
Dever AI see Schweizer E Feinberg SS see Opler LA VL: Neuroleptic Malignant Syndrome: A
Devlin MJ see Ames-Frankel J Fennig S, Mauas L. Ofloxacin-induced de- Clinical Approach. Jan 31
Devous MD Sr. Comparison of SPECT applica- lirium [letter]. Apr 137-138 Gold DD Jr. Review of Howells JG (ed): The
tions in neurology and psychiatry. Nov suppl Fiester SJ see Kane JM Concept of Schizophrenia: Historical Per-
13-19 Fieve RR see Dunner DL spectives. May 175-176
Dewan M see Masand P Figiel GS, Zorumski CF, Doraiswamy PM, Gold DD Jr. Review of Volkow ND, Wolf AP
Dewan MJ see Popli AP Mattingly GW, Jarvis MR. Simultaneous (eds): Positron Emission Tomography in
Dilsaver SC, Qamar AB, Del Medico VJ. Ef- major depression and panic disorder: treat- Schizophrenia Research. Apr 140
ficacy of bupropion in winter depression: re- ment with electroconvulsive therapy. Jan 12- Goldstein BJ see Dominguez RA
sults of an open trial. July 252-255 15 Golwyn DH, Sevlie CP. Paraphilias, nonpara-
Dimeff RJ see Malone DA Jr Fleischhacker WW see Barnas C; Schwitzer J philic sexual addictions, and social phobia [let-
Dinwiddie SH, Reich T, Cloninger CR. Psy- Fletcher JR see Ratey JJ ter]. Sept 330
chiatric comorbidity and suicidality among Fogelson DL, Bystritsky A, Pasnau R. Bupro- Goodman WK. Introduction. Obsessive com-
intravenous drug users. Oct 364-369 pion in the treatment of bipolar disorders: the pulsive disorder: integrating theory and prac-
Djenderedjian AH, Ritchie MA. Review of same old story? Dec 443-446 tice. Apr suppl 3
Amchin J: Psychiatric Diagnosis: A Bio- Fox I see Rickels K Goodman WK, McDougle CJ, Price LH.
psychosocial Approach. July 259-260 Frank E see Thase ME Pharmacotherapy of obsessive compulsive
Dominguez RA. Serotonergic antidepressants Friedman JH see Caley CF disorder. Apr suppl 29-37
and their efficacy in obsessive compulsive Friedman M see Galynker I Goodman WK see Barr LC
disorder. Oct suppl 56-59 Friedman R see Krupp LB Gordon MA. Carbamazepine-associated throm-
Dominguez RA, Goldstein BJ. Suicidal and Fuchs D, Weiss G, Wachter H. Pathogenesis bocytopenia [letter with reply]. Oct 378
homicidal ideations emerging during a pla- of chronic fatigue syndrome [leiter with re- Gorman JM see Coplan JD
cebo period [letter]. May 171 ply]. Aug 296 Greason FC see Hill MA
Dommisse J. Bipolar disorder and Crohn’s dis- Fuller RW. Basic advances in serotonin phar- Green AI see Berman I
ease [letter]. Jan 29 macology. Oct suppl 36-45 Greenblatt DJ. Pharmacology of benzodiaze-
Doraiswamy PM see Figiel GS Gaffney M see Serban G pine hypnotics. June suppl 7—13
Douglas CJ see Wolk SI Galderisi S see Catapano F Greist JH. Integrated approach to treatment of
Dunbar GC see Claghorn JL; Dunner DL Galynker I, McQuistion H, Kahn RS, Fried- obsessive compu!sive disorder. Apr suppl
Dunner DL, Cohn JB, Walshe T III , Cohn man M. Fluoxetine treatment of slow eating 38-41
CK, Feighner JP, Fieve RR, Halikas JP, [letter]. Aug 295-296 Greist JH see DasGupta K
Hartford JT, Hearst ED, Settle EC Jr, Ganguli R see Levin H Groves L see Lazarus LW
Menolascino FJ, Muller DJ. Two com- Garde IB see Miller LS Gupta MA. Dangerous driving and eating dis-
bined, multicenter double-blind studies of Garlow SJ see Harrington MA orders [letter]. Nov 416
paroxetine and doxepin in geriatric patients Gelenberg AJ. Closing remarks. Use of benzo- Gurrera RJ, Chang SS, Romero JA. Com-
with major depression. Feb suppl 57-60 diazepine hypnotics: a scientific examination parison of diagnostic criteria for neuroleptic
Dunner DL, Dunbar GC. Optimal dose regi- of a clinical controversy. Dec suppl 87 malignant syndrome. Feb 56-62
men for paroxetine. Feb suppl 21-26 Gelenberg AJ. If not now, when [editorial]? Halikas JP see Dunner DL
DuRand CJ, Knutsen EJ. Psychiatrists and Aug 266 Hamann GL, Wells BG. Reply to Reinke M:
physical illness: clarification [letter]. June Gelenberg AJ. Imperfect drugs in an imperfect High incidence of haloperidol decanoate in-
213 world [editorial]. Feb 39-40 jection site reactions [letter]. Nov 415-416
DuRand CJ see Berman I Gelenberg AJ. Introduction. Use of benzodiaze- Hamer T see Thase ME
Ehmann TS see Smith GN pine hypnotics: a scientific examination of a Hamilton MS, Opler LA. Akathisia, suicidal-
Eisen JL see Rasmussen SA clinical controversy. Dec suppl 3 ity, and fluoxetine. Nov 401-406
El-Mallakh RS. HIV-related psychosis [letter]. Gelenberg AJ. To all a good year [editorial]. Hanson DR see Pfister GM
Aug 293-294 Dec 424-425 Harrington MA, Zhong P, Garlow SJ,
Engelhardt CL see Walsh JK Gelernter CS, Stein MB, Tancer ME, Uhde Ciaranello RD. Molecular biology of seroto-
Escobar JI see Goates MG TW. Examination of syndromal validity and nin receptors. Oct suppl 8-27
Evans DL see Kane JM diagnostic subtypes in social phobia and Harris GJ see Hoehn-Saric R
Fabre LF. Six-week, double-blind trial of par- panic disorder. Jan 23-27 Hartford JT see Dunner DL
oxetine, imipramine, and placebo in de- George MS, Post RM, Ketter TA, Marangell Hartman C see Lazarus LW
pressed outpatients. Feb suppl 40-43 LB, Pazzaglia PJ. Clarification of alpidem Hawkins JW. Nonsedating treatments for
Fadden ISP. Nifedipine and nonresponse to an- as an antidepressant [letter with reply]. Feb Alzheimer’s patients with behavioral prob-
tidepressants [letter with reply]. Nov 416-417 68 lems [letter with reply]. Mar 101-102
Fallon BA see Stein DJ George MS, Trimble MR. Fluvoxamime-in- Hay J. Injection site reactions [letter]. July 256
Fankhauser MP, Karumanchi VC, German duced frontal lobe syndrome in a patient with Head LA see Jackson CW
ML, Yates A, Karumanchi SD. Double- comorbid Gilles de la Tourette’s syndrome Hearst ED see Dunner DL
J Clin Psychiatry 53:12, December 1992
Author Index: Volume 53
Hendricks SE see Balogh S Kalinske RW see Jonas J Leonard HL see Rapoport JL
Herzog DB, Keller MB, Lavori PW, Kenny Kambhampati RK see Levin H Leong GB see Silva JA
GM, Sacks NR. Prevalence of personality Kane JM, Evans DL, Fiester SJ, Mirin SM, Leuchter AF see Szuba MP
disorders in 210 women with eating disor- Pincus HA, Schatzberg AF, Cole JO, Pop- Levenson JA. Should psychostimulants be used
ders. May 147-152 per CW. Psychopharmacological screening to treat delirious patients with depressed
Hill FS. Review of Dulcan MK, Popper CW: criteria: APA Committee on Research on mood [letter]? Feb 69
Concise Guide to Child and Adolescent Psy- Psychiatric Treatments [special article]. June Levin H, Chengappa KNR, Kambhampati
chiatry. Feb 70-71 184-196 RK, Mahdavi N, Ganguli R. Should chronic
Hill JL see Rubenstein CS Kane JM see Glazer WM treatment-refractory akathisia be an indication
Hill MA, Greason FC. Loperamide dependence Kang J see Balogh S for the use of clozapine in schizophrenic pa-
[letter]. Dec 450 Kartan U see Lazarus LW tients? July 248-251
Hirschfeld RMA. Closing remarks. Current Karumanchi SD see Fankhauser MP Levine SB. Review of Socarides CW, Volkan
perspectives on panic disorder and major de- Karumanchi VC see Fankhauser MP VD (eds): The Homosexualities: Reality,
pression. Mar suppl 36 Kaslow KA, Rosse RB, Zeller JA, Nagy MS, Fantasy, and the Arts. Oct 381
Hirschfeld RMA. Introduction. Current per- Deustch SI. Phenothiazine-induced lupus an- Levitt AJ see Cooke RG
spectives on panic disorder and major depres- ticoagulant [letter]. Mar 103-104 L’Heureux F see Rubenstein CS
sion. Mar suppl 3-4 Keck PE Jr, McEIroy SL. Ratio of plasma flu- Licinio J see Miller HL
Hoehn-Saric R, Harris GJ, Pearlson GD. Re- oxetine to norfluoxetine concentrations and Liebowitz MR see Carrasco JL; Stein DJ
ply to George MS: Fluvoxamine-induced associated sedation. Apr 127-129 Lindem KJ see Ratey JJ
frontal lobe syndrome in a patient with co- Keitner GI. Review of Becker J, Kleinman A Lingam VR see Lazarus LW
morbid Gilles de la Tourette’s syndrome and (eds): Psychosocial Aspects of Depression. Linnoila VMI, Virkkunen M. Aggression, sui-
obsessive compulsive disorder [letter]. Oct Feb 71 cidality, and serotonin. Oct suppl 46-51
379-380 Keller MB, Baker LA. Clinical course of panic Llorente MD, Currier MB, Norman SE,
Hoffman MK see Stewart JT disorder and depression. Mar suppl 5-8 Mellman TA. Night terrors in adults: phe-
Hollander E, McCarley A. Yohimbine treat- Keller MB see Herzog DB nomenology and relationship to psychopa-
ment of sexual side effects induced by seroto- Kellner CH see Jackson CW thology. Nov 392-394
nin reuptake blockers. June 207-209 Kenny GM see Herzog DB Locke CA see Rothschild AJ
Hollander E, Mullen LS, Carrasco JL, Ketter TA see George MS Lydiard RB see Deci PA; Villeponteaux VA
DeCaria CM, Stein DJ. Symptom relapse in Kiev A. Double-blind, placebo-controlled study MacEwan GW see Smith GN
bulimia nervosa and obsessive compulsive of paroxetine in depressed outpatients. Feb Mahdavi N see Levin H
disorder after treatment with serotonin an- suppl 27-29 Malen DG. Parnate formulation change [letter
tagonists [letter]. Jan 28 Kiev A see Claghorn JL with reply]. Sept 328-329
Hollander E see Carrasco JL; Stein DJ King P. Review of Esman AH: Adolescence Mallinger AG see Thase ME
Honer WG see Smith GN and Culture. Aug 298 Mallya AR, Roos PD, Roebuck—Colgan K.
Hummer M see Barnas C Klein DF see Stein DJ Restraint, seclusion and clozapine. Nov 395—
Ibanez-Rojo V see Iruela LM Klerman GL. Treatments for panic disorder. 397
Innis RB. Neuroreceptor imaging with SPECT. Mar suppl 14-19 Malone DA Jr, Dimeff RJ. Use of fluoxetine
Nov suppl 29-34 Klett CJ. Review of triazolam data. Dec supp! in depression associated with anabolic steroid
Iruela LM, Ibanez-Rojo V, Gilaberte I, 61-67 withdrawal: a case series. Apr 130-132
Oliveros SC. New possible indications of Knutsen EJ see DuRand CJ Mandos LA see Schweizer E
pimozide [letter with reply]. May 172-173 Kobak KA see DasGupta K Manning K see Wroblewski B
Isaac G. Misdiagnosed bipolar disorder in ado- Kores RC. Review of Butcher JN, Graham JR, Marangell LB see George MS
lescents in a special educational school and Williams CL, Ben-Porath YS: Development Margolis D see Barklage NE
treatment program. Apr 133-136 and Use of the MMPI-2 Content Scales. Mar Martinez IL see Vicente YMR
Jackson CW, Head LA, Keiiner CH. Catato- 105-106 Maruyama N see Snyder S
nia associated with bupropion treatment [let- Kornhuber J see Weller M Masand P, Dewan M. Suicidality and fluoxe-
ter]. June 210 Kravitz K see Miller LS tine revisited [letter with reply]. Mar 102-103
Jacobsen FM. Fluoxetine-induced sexual dys- Krupp LB, Friedman R, Mendelson WB. Re- Masand PS see Popli AP
function and an open trial of yohimbine. Apr ply to Wachter H: Pathogenesis of chronic fa- Masica DN see Wheadon DE
119-122 tigue syndrome [letter]. Aug 296 Mattingly GW see Figiel GS
Jarvis MR see Figiel GS Kupfer DJ. Closing remarks. Use of benzodiaz- Mauas L see Fennig S
Jefferson JW. Is tranylcypromine really me- epine hypnotics. a scientific exariination of a Mavissakalian M. Review of Turner SM,
tabolized to amphetamine [letter with reply]? clinical comiroversy. Dec supp) “4-85 Calhoun iS, Adams {4© ieds): Handbook of
Dev 48-451 Kupfer DJ see Thase ME Clinical Behavior Therasy. Nov 419
Jefferson JW. Potassium supplementation in Landbloom R see Pfister GM Mazza DL. Review of Schwartz HJ, Silver A-L
lithium patients: a timely intervention or pre- Laraia MT see Villeponteaux VA (eds): ///ness in the Analyst. Oct 382
mature speculation? Oct 370-372 Larocca FEF. Review of Harper-Giuffre H, McCarley A see Hollander E
Jefferson JW see Barklage NE; DasGupta K MacKenzie KR (eds): Group Psychotherapy McDougle CJ see Barr LC; Goodman WK
Joffe RT see Cooke RG for Eating Disorders. Nov 418 McElroy SL see Keck PE Jr
Johnson AM see Tulloch IF Lavori PW see Herzog DB McQuistion H see Galynker I
Jonas JM, Coleman BS, Sheridan AQ, Lazarus LW, Winemiller DR, Lingam VR, Mellman TA see Liorente MD
Kalinske RW. Comparative clinical profiles Neyman I, Hartman C, Abassian M, Mendelson WB. Clinical distinctions between
of triazolam versus other shorter-acting hyp- Kartan U, Groves L, Fawcett J. Efficacy long-acting and short-acting benzodiazepines.
notics. Dec suppl 19-31 and side effects of methylphenidate for Dec suppl 4-7
Jones JS see Winchel RM poststroke depression. Dec 447-449 Mendelson WB. Introduction. Current strategies
Kadisi: W see Ratey JJ Leary JM see Wroblewski BA in the treatment of insomnia. June suppl 3
Kafka MP, Prentky R. Comparative study of Leckman JF see Cohen AJ Mendelson WB. Review of Koulack D: To
nonparaphilic sexual addictions and paraphil- Lee C see Schnur DB Catch a Dream. Aug 297
ias in men. Oct 345-350 Lefler LA see Stewart JT Mendelson WB see Krupp LB
Kafka MP, Prentky R. Fluoxetine treatment of Lenox RH, Newhouse PA, Creelman WL, Mendez MF. Mania self-induced with cough
nonparaphilic sexual addictions and paraphil- Whitaker TM. Adjunctive treatment of syrup [letter]. May 173-174
ias in men. Oct 351-358 manic agitation with lorazepam versus halo- Menolascino FJ see Dunner DL
Kahn RS see Galynker I peridol: a double-blind study. Feb 47-52 Mercier MA, Stewart JW, Quitkin FM. Pilot
J Clin Psychiatry 53:12, December 1992